Michele Korfin joined Gamida Cell’s leadership team as chief operating and chief commercial officer in July 2020. Prior to Gamida Cell, Michele served as chief operating officer at TYME Technologies. From 2016–2018, she was vice president of market access at Kite Pharma, where she oversaw market access strategy, including payer relations, reimbursement and government affairs for YESCARTA®, the first approved CAR-T therapy in lymphoma. She also worked closely with the manufacturing and supply chain teams at Kite to prepare for FDA approval and commercialization. Before joining Kite, Michele spent more than a decade at Celgene in a variety of key strategic and operational roles, including in commercial leadership and oversight of the global development programs for REVLIMID®, a therapy for lymphoma and chronic lymphocytic leukemia. She also led the Celgene oncology sales force of over 120 representatives who were responsible for $650 million in revenue for ABRAXANE®, which is now a standard of care in pancreatic cancer. Michele has also held positions at Merck & Co. as a manufacturing scientist, Bain & Company as a consultant and Schering-Plough in sales and marketing.
Michele holds an MBA from Harvard Business School and a B.S. in pharmacy from Rutgers University. She is also on the Board of Trustees of BioNJ, the organization that represents the biotechnology industry for New Jersey.